QNCX Stock Price, Que Therapeutics, Inc. Quote, Chart

Market Summary

USD0.90-0.02

Market Closed

-2.17%

QNCX Stock Price

View Fullscreen

QNCX RSI Chart

QNCX Valuation

Market Cap

38.9M

Price/Earnings (Trailing)

-1.28

Price/Free Cashflow

-1.68

QNCX Price/Earnings (Trailing)

QNCX Profitability

Return on Equity

-40.82%

Return on Assets

-19.01%

Free Cashflow Yield

-59.49%

QNCX Fundamentals

QNCX Earnings

Earnings (TTM)

-30.3M

Earnings Growth (Yr)

9.02%

Earnings Growth (Qtr)

-25.35%

Breaking Down QNCX Revenue

Last 7 days

-5.3%

Last 30 days

-10%

Last 90 days

-29.7%

How does QNCX drawdown profile look like?

QNCX Financial Health

Current Ratio

7.16

Debt/Equity

0.18

Debt/Cashflow

-1.71

QNCX Investor Care

Shares Dilution (1Y)

19.15%

Diluted EPS (TTM)

-0.76

Tracking the Latest Insider Buys and Sells of Quince Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 16, 2024	thye dirk	acquired	190,791	0.793211	240,530	chief executive officer
Dec 14, 2023	lamond david	bought	23,532	1.04	22,627	-
Dec 13, 2023	lamond david	bought	22,627	1.00	22,627	-
Dec 12, 2023	lamond david	bought	22,773	1.02	22,327	-
Dec 12, 2023	lamond david	bought	300	1.00	300	-
Dec 07, 2023	lamond david	bought	19,314	1.01	19,123	-
Dec 06, 2023	lamond david	bought	19,505	1.02	19,123	-
Dec 05, 2023	lamond david	bought	19,314	1.01	19,123	-
Dec 01, 2023	lamond david	bought	13,515	0.94	14,378	-
Nov 30, 2023	lamond david	bought	12,940	0.9	14,378	-

Which funds bought or sold QNCX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-125,728	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-12,604	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	28,043	28,043	-%
May 15, 2024	Royal Bank of Canada	added	68.7	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	1,385	146,805	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-13,843	-	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-8.46	-256,489	3,124,510	0.32%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-9.7	-5,519	56,900	-%
May 15, 2024	Mariner, LLC	unchanged	-	740	78,518	-%
May 15, 2024	MORGAN STANLEY	reduced	-7.56	-637	8,904	-%

Are Funds Buying or Selling QNCX?

Are funds buying QNCX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own QNCX

No. of Funds

Unveiling Quince Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	7.5%	3,220,000	SC 13G/A
Feb 12, 2024	sofinnova partners sas	5.1%	2,178,150	SC 13G
Feb 07, 2024	bml investment partners, l.p.	0.0%	0	SC 13G/A
Dec 15, 2023	genextra s.p.a.	5.89%	2,525,950	SC 13G

Recent SEC filings of Quince Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Apr 24, 2024	DEFA14A	DEFA14A
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	ARS	ARS
Apr 11, 2024	PRE 14A	PRE 14A
Apr 01, 2024	S-8	Employee Benefits Plan
Apr 01, 2024	10-K	Annual Report
Feb 15, 2024	8-K	Current Report
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	3	Insider Trading

Peers (Alternatives to Quince Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Quince Therapeutics, Inc. News

Latest updates

Quince Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.1%	159	168	85.00	89.00	93.00	104	110	118	116	133	147	161	175	189	205	219	231	124	133	143	71.00
Current Assets	-9.0%	70.00	77.00	85.00	89.00	92.00	94.00	98.00	99.00	96.00	112	119	136	150	138	143	152	169	106	124	134	64.00
Cash Equivalents	5.1%	22.00	21.00	22.00	23.00	47.00	45.00	32.00	47.00	68.00	70.00	62.00	74.00	85.00	67.00	64.00	66.00	86.00	51.00	45.00	44.00	21.00
Net PPE	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Goodwill	-2.2%	17.00	18.00	-	-	-	-	-	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.8%	85.00	83.00	42.00	2.00	3.00	3.00	5.00	6.00	10.00	15.00	15.00	19.00	18.00	17.00	17.00	14.00	13.00	9.00	6.00	7.00	4.00
Current Liabilities	2.8%	10.00	10.00	2.00	2.00	3.00	3.00	5.00	6.00	10.00	14.00	14.00	19.00	18.00	17.00	16.00	14.00	13.00	9.00	6.00	7.00	4.00
Long Term Debt	0.7%	14.00	13.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-12.8%	74.00	85.00	83.00	87.00	90.00	101	105	112	106	119	133	142	156	172	188	205	218	115	127	136	-
Retained Earnings	-3.5%	-330	-319	-310	-305	-300	-288	-282	-274	-258	-236	-213	-191	-169	-146	-126	-104	-86.98	-69.81	-57.43	-47.57	-38.51
Additional Paid-In Capital	0.4%	403	402	393	392	391	389	387	387	365	355	346	333	326	319	314	309	305	185	185	184	0.00
Shares Outstanding	0.6%	43.00	43.00	36.00	36.00	36.00	36.00	33.00	31.00	30.00	30.00	30.00	30.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	50.00	-	-	-	70.00	-	-	-	1,240	-	-	-	1,370	-	-	-	669	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-37.4%	-8,353	-6,078	-4,818	-3,827	-3,569	-5,835	-6,697	-15,415	-16,091	-14,418	-17,342	-17,562	-13,610	-13,276	-12,371	-14,392	-10,779	-10,950	-8,796	-6,315	-7,216
Share Based Compensation	17.3%	1,274	1,086	1,331	1,322	1,481	1,632	694	5,052	9,240	8,493	7,619	6,750	6,991	4,959	4,158	3,398	1,955	577	912	377	190
Cashflow From Investing	65.4%	8,914	5,390	3,635	-20,323	5,540	18,666	-8,826	-5,251	13,413	20,919	766	5,624	31,643	15,826	10,371	-5,947	-72,681	17,704	9,222	-47,837	3,164
Cashflow From Financing	233.3%	190	57.00	10.00	26.00	50.00	-18.00	-5.00	108	622	990	4,705	672	441	45.00	90.00	889	117,852	-530	-	77,832	64.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

QNCX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,702	$ 3,230
General and administrative	4,971	3,826
Intangible asset impairment charge	0	5,900
Fair value adjustment for contingent consideration	2,545	0
Total operating expenses	11,218	12,956
Loss from operations	(11,218)	(12,956)
Fair value adjustment for long-term debt	(388)	0
Interest income	887	700
Other expense, net	(399)	(246)
Net loss before income tax benefit	(11,118)	(12,502)
Income tax (expense) benefit	(31)	248
Net loss	(11,149)	(12,254)
Other comprehensive loss:
Foreign currency translation adjustments	(1,229)	92
Unrealized gain on available-for-sale securities	7	235
Total comprehensive loss	$ (12,371)	$ (11,927)
Net loss per share - basic	$ (0.26)	$ (0.34)
Net loss per share - diluted	$ (0.26)	$ (0.34)
Weighted average shares of common stock outstanding - basic	43,010,212	35,855,200
Weighted average shares of common stock outstanding - diluted	43,010,212	35,855,200

QNCX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 21,813	$ 20,752
Short-term investments	46,010	54,307
Prepaid expenses and other current assets	2,616	2,381
Total current assets	70,439	77,440
Property and equipment, net	234	234
Operating lease right-of-use assets	576	385
Goodwill	17,245	17,625
Intangible asset	62,253	63,672
Other assets	8,467	8,466
Equity investments in Lighthouse Pharmaceuticals, Inc.	78	78
Total assets	159,292	167,900
Current liabilities:
Accounts payable	2,070	2,033
Short-term contingent consideration	4,748	4,103
Accrued expenses and other current liabilities	3,020	3,436
Total current liabilities	9,838	9,572
Long-term debt	13,518	13,429
Long-term operating lease liability	480	321
Long-term contingent consideration	55,503	53,603
Deferred tax liabilities	5,177	5,304
Other long-term liabilities	599	587
Total liabilities	85,115	82,816
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 authorized, (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 43,215,233 and 42,973,215 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	43	43
Additional paid in capital	403,102	401,638
Accumulated other comprehensive income	1,825	3,047
Accumulated deficit	(330,793)	(319,644)
Total stockholders’ equity	74,177	85,084
Total liabilities and stockholders’ equity	$ 159,292	$ 167,900

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

CEO	Dr. Dirk Thye M.D.
WEBSITE	quincetx.com
INDUSTRY	Biotechnology
EMPLOYEES	21

Quince Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Quince Therapeutics, Inc.? What does QNCX stand for in stocks?

QNCX is the stock ticker symbol of Quince Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quince Therapeutics, Inc. (QNCX)?

As of Fri May 17 2024, market cap of Quince Therapeutics, Inc. is 38.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QNCX stock?

You can check QNCX's fair value in chart for subscribers.

What is the fair value of QNCX stock?

You can check QNCX's fair value in chart for subscribers. The fair value of Quince Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quince Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QNCX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quince Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether QNCX is over valued or under valued. Whether Quince Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Quince Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QNCX.